Original Research

69 Heart Rate Response to a Timed Walk and Cardiovascular Outcomes in Older Adults: The Cardiovascular Health Study
Girotra, S. (Iowa City, Iowa); Kitzman, D.W. (Winston-Salem, N.C.); Kop, W.J. (Tilburg); Stein, P.K. (St. Louis, Mo.); Gottdiener, J.S. (Baltimore, Md.); Mukamal, K.J. (Boston, Mass.)

76 Long-Term Outcome of Patients with Antiphospholipid Syndrome Who Undergo Percutaneous Coronary Intervention

83 Outcome of Patients Presenting with ST Elevation Myocardial Infarct and Cardiogenic Shock: A Contemporary Single Center’s Experience
Greenberg, G.; Assali, A.; Assa-Vaknin, H.; Brosh, D.; Teplitsky, I.; Battler, A.; Kornowski, R.; Lev, E.I. (Petach Tikva/Tel Aviv)

93 Inhibitory Effect of p53 Upregulated Modulator of Apoptosis Targeting siRNA on Hypoxia/Reoxygenation-Induced Cardiomyocyte Apoptosis in Rats

119 Administration of Perflutren Contrast Agents during Transthoracic Echocardiography Is Not Associated with a Significant Increase in Acute Mortality Risk
Goldberg, Y.H.; Ginelli, P.; Siegel, R.; Ostfeld, R.J.; Schaefer, M.; Spevack, D.M. (Bronx, N.Y.)

Turning Basic Research into Clinical Success

104 Beta-Adrenergic Receptors, from Their Discovery and Characterization through Their Manipulation to Beneficial Clinical Application
Wachter, S.B.; Gilbert, E.M. (Salt Lake City, Utah)

Novel Insights from Clinical Experience

89 Brugada Syndrome Masked by Ibutilide Treatment in a Patient with Atrial Flutter

126 Hypothermia: A Double-Edged Sword
Todaro, M.C.; Oreto, L. (Messina); Gupta, A.; Bajwa, T.; Khandheria, B.K. (Milwaukee, Wisc.)

(Continued on inside front cover)
Short Communication

129 The Association of Red Cell Distribution Width with Glycated Hemoglobin among Healthy Adults without Diabetes Mellitus
Veeranna, V.; Zalawadiya, S.K.; Panaich, S.S.; Ramesh, K.; Afonso, L. (Detroit, Mich.)

Letter to the Editors

101 Unfavourable Effect of Pulmonary Arterial Dilatation in Pulmonary Hypertension
Tamura, Y.; Sukegawa, H.; Ono, T.; Sano, M.; Fukuda, K. (Tokyo)

103 Author’s Reply
Badagliacca, R. (Rome)

113 Raising Doubts about the Pathogenicity of Mitochondrial DNA Mutation m.3308T>C in Left Ventricular Hypertrabeculation/Noncompaction
Salas, A. (Santiago de Compostela); Elson, J.L. (Newcastle upon Tyne)

116 Pathogenicity of the Transition m.3308T>C in Left Ventricular Hypertrabeculation/Noncompaction
Zarrouk Mahjoub, S.; Mehri, S.; Ourda, E; Boussaada, R.; Mechmeche, R.; Ben Arab, S. (Tunis); Finsterer, J. (Vienna)
(Continued)

Editorial Board

L.D. Hillis, San Antonio, Tex.
C.A. Hochreiter, New York, N.Y.
M. Hori, Osaka
S.K.S. Huang, Temple, Tex.
X. Huang, Boca Raton, Fla.
B.K. Kantharia, Houston, Tex.
J.S. Karliner, San Francisco, Calif.
R.E. Kerber, Iowa City, Iowa
N.Z. Kerin, Detroit, Mich.
A. Kimchi, Los Angeles, Calif.
R.N. Kitsis, Bronx, N.Y.
P. Kligfield, New York, N.Y.
X. Kong, Nanjing
M.A. Konstam, Boston, Mass.
J.B. Kostis, New Brunswick, N.J.
P. Kowey, Wynnewood, Pa.
K.H. Krieger, New York, N.Y.
H. Krum, Melbourne
E. Kuschnir, Córdoba
H. Kusuoka, Osaka
J.M. Lazar, Brooklyn, N.Y.
C.V. Leier, Columbus, Ohio
M.C. Limacher, Gainesville, Fla.
R.J. Lipicky, North Potomac, Md.
T.F. Lüscher, Zurich
E.I. Marcus, Tuscon, Ariz.
A.J. Marian, Houston, Tex.
J.D. Marmur, Brooklyn, N.Y.
F.A. Martinez, Córdoba
M.G. Massad, Chicago, Ill.
F.H. Messerli, New York, N.Y.
J. Midwall, Atlantis, Fla.
A.B. Miller, Jacksonville, Fla.
R.M. Mills, Raritan, N.J.
J.E. Mitchell, Brooklyn, N.Y.
R.J. Myerburg, Miami, Fla.
J. Narula, Orange, Calif.
J.V. Nixon, Richmond, Va.
H. Oh, Okayama
P. Pibarot, Quebec
B. Pitt, Ann Arbor, Mich.
G.M. Pohost, Los Angeles, Calif.
E.N. Prystowsky, Indianapolis, Ind.
N. Reichek, Roslyn, N.Y.
W.J. Remme, Rhoon
R. Roberts, Ottawa
W.C. Roberts, Dallas, Tex.
R. Rosenhek, Vienna
J.N. Ruskin, Boston, Mass.
F. Ruschitzka, Zurich
M.E. Sarano, Rochester, Minn.
V.L. Serebruany, Towson, Md.
M.R. Starling, Mesa, Ariz.
P. Supino, Brooklyn, N.Y.
J.L. Swain, La Jolla, Calif.
K. Swedberg, Göteborg
A.J. Tajik, Rochester, Minn.
L. Tavazzi, Cotignola
J.R. Teerlink, San Francisco, Calif.
M. Tendera, Katowice
U. Thadani, Oklahoma City, Okla.
K. Thygesen, Aarhus
N.K. Wenger, Atlanta, Ga.
W.B. White, Farmington, Conn.
J.T. Willerson, Houston, Tex.
R.G. Williams, Los Angeles, Calif.
K.K.-Y. Wu, Zhunan Town
F. Zannad, Nancy
B.L. Zaret, New Haven, Conn.
D.P. Zipes, Indianapolis, Ind.
Submission

‘Cardiology’ publishes original reports in research and observations pertaining to cardiovascular physiology, epidemiology, pharmacology, disease and therapy. Only original papers written in English are considered. The articles should be readily comprehensible to a reader who is fluent in English. Therefore, all manuscripts originating from non-English-speaking authors must be edited prior to submission to assure that standard English grammar and usage are observed. This may require help from a colleague or other editorial assistant. It must be evident from the covering letter that this has been achieved. Manuscripts should be submitted using the online submission website:

www.karger.com/crd

If you have any problems with submission, please contact:

S. Karger AG
Editorial Office ‘Cardiology’
P.O. Box
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1357
Fax +41 61 306 1434
E-Mail crd@karger.ch

All manuscripts must be accompanied by a covering letter signed by all authors. Assurance should be given that the manuscript is not under simultaneous consideration by any other publication and that there are no conflicts of interest, see below. The preferred word processing package is Word for Windows®. Presentation of manuscripts should conform with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see N Engl J Med 1997;336:309–315).

Main Sections

1. Original Research

2. Original Research – Clinical Trial Design

Submissions will be accepted reporting the study design protocols of planned clinical trials that have been appropriately registered with regulatory authorities. These submissions will be limited to 4500 words and 35 references.

3. Review

4. Turning Basic Research into Clinical Success

One to two focused review articles are published in each issue, and should offer an overview of existing concepts and literature in a format assimilable to the largely clinical cardiologist readership, i.e. a readership based on limited sophistication as to methods and terminology associated with cell and molecular biology. Most manuscripts are submitted upon invitation. Authors planning to submit an unsolicited paper are requested to contact the Editorial Office with an outline of the intended contribution. All submissions are subject to peer review. These articles are available also to nonsubscribers in free access on the journal’s website. Submissions should comprise no more than 4,500 words and 50 references. They should have an abstract of approximately 200 words and about 5 key words should be provided.

5. Letter to the Editor

Letters to the Editor (max. 1,500 words, including references) are encouraged if they directly concern articles previously published in this journal and is seen to have interest to the general readership. Letters should be brief and to the point, preferably no more than 200 words and 3 tables or figures. Responses to Letters to the Editor should be submitted as Letters to the Editor. The exact postal address of the correspondent author complete with postal code must be indicated. Any abbreviation should not exceed 5 words and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. Submission of an article for publication implies the transfer of the copyright from the author’s earlier work (duplicate publication or ‘self-plagiarism’). Plagiarism includes, but is not limited to, verbatim copying without attribution marks, close paraphrasing or summarization of sentences or narrative passages without citing source, and duplication of figures, graphs, images or data without acknowledgement of their origins. Authors also should not submit a previously published manuscript or a section of a previously published manuscript, even when re-titled, otherwise re-worded or augmented, without clearly identifying its relation to the author’s earlier work (duplicate publication or ‘self-plagiarism’). For additional guidance, see Roig M.: Plagiarism and self-plagiarism: What every author should know. Biochimica Medica 2010;20:295–300.

Arrangement

Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head. Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address. Key words: Please supply 3–10 key words in English that reflect the content of the paper.

For submissions to Main Sections 1, 2 and 3:

Original Research, Original Research – Clinical Trial Design, and Review Papers

Abstract: The abstract is an essential and most read part of the paper. It should be printed on a separate page, up to 200 words, factual, free of abbreviations (except as specifically defined within the abstract text at first use) and should be structured as follows:

Objective: Describe the purpose of the study and the problem addressed, should include at least one sentence providing the rationale or justification for the study. Methods: Should explain how the study was performed (samples and/or population, procedures, analytical methods).

Results: Should describe the main findings with specific data and their statistical significance, if possible. Conclusions: Should contain a succinct interpretation of the inferences to be drawn from results.
Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figures a legend, also prepared on a separate sheet. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author’s name. b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions at http://www.karger.com/crd/).

Color illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples

(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.


Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be used in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov,.avi,.mpeg).

Authors’ Choice
With this option the author can choose to make his article freely available online against a one-time fee of CHF 3000.–. This fee is independent of any standard charges for supplementary pages, color images etc. which may apply. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice service, we will send your article immediately upon publishing, accelerating the accessibility of your work with the usual embargo. More details on NIH’s Public Access Policy are available at http://publicaccess.nih.gov/FAQ.htm#a1

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Page Charges
There are no page charges for papers of 6 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.–. The allotted size of a paper is equal to approx. 18 manuscript pages (including tables, illustrations and references).

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
The European Society of Cardiology presents the world’s premier conference on the science, management and prevention of cardiovascular disease.

This year’s spotlight is “From bench to practice”

Advance programme now available online: www.escardio.org/ESC2012programme

400+ scientific sessions to

△ Experience the new organisation in themed villages*
■ Exchange with leading experts during interactive sessions
● Discover the very latest clinical trial results

*Find out more about the villages at www.escardio.org

Register Now!

Online at www.escardio.org
31 July 2012: Advance registration deadline

Win a free congress registration

Scan this QR code (or visit www.escardio.org/esc2012-prize) to enter the prize draw* for a free registration for ESC Congress 2012 in Munich

*Rules and regulations available at www.escardio.org

2011 Key figures: 5 days of scientific sessions △ 32 000+ healthcare professionals from 150+ countries ■ 10 800+ abstracts submitted ▲ 4 200+ selected abstracts ▼ 70 industry sponsored sessions ▲ 200 exhibiting companies ■ ▲ unique & unlimited opportunities to network!

www.escardio.org
Contents

See the journal website for contents
The 2nd International Conference on
PreHypertension and CardioMetabolic Syndrome
PreHT 2013
January 31 - February 3, 2013, Barcelona, Spain

“Prevention, Diagnosis and Treatment of End-Organ Damage in PreHypertension and the CardioMetabolic Syndrome”

Co-Chairs
Daniel A. Duprez, USA
Hermann Haller, Germany
Basil S. Lewis, Israel
Reuven Zimlichman, Israel

Organizing Committee
Luis M. Ruisope, Spain, Chair
Olga Gonzalez Albarran
Sara Artola
Mariano de la Figuera
Josep Maria Galceran
Ramon Gomis
Jose Zamorano

Honorary Chairmen
Stevo Julius, USA
Giuseppe Mancia, Italy

Conference Topics will include:

- Metabolic Syndrome and Vitamin D
- Prediabetes - Mechanisms, Diagnosis and Management
- Pre-Labs of CV Risk Factors - Boosting Risk of Events and Deciding Who Should be Treated
- Benefits of Achieving Optimal Risk Factors Level - When, How and with What?
- Pre-Hypertension and Metabolic Syndrome in Different Populations - Epidemiologic Aspects
- Total Cardiovascular Risk Evaluation and Management
- Arterial Properties, Evaluation and Treatment in Metabolic Syndrome
- Cardiac Markers of Pre-Clinical Disease in Metabolic Syndrome Patients

The full topic list can be viewed at the Conference Website

Call for Abstracts is available online:
Deadline: September 13, 2012

Benefit from reduced registration fees until
Valid until October 15, 2012

For more information, please visit our website: www.prehypertension.org

Conference Secretariat:
18 Avenue Louis-Casai, 1209 Geneva, Switzerland
Tel: +41 22 533 0948, Fax: +41 22 580 2953
E-mail: secretariat@prehypertension.org
SMi presents their inaugural conference on...

Diabetes, Cardiovascular & Renal Complications

Wednesday 28th & Thursday 29th November 2012
Copthorne Tara Hotel, London

KEY SPEAKERS INCLUDE:

Riccardo Perfetti
Vice President Global Medical Affairs, Diabetes Division
Sanofi-Aventis

James F. List
Vice President, Full Development
Bristol-Myers Squibb

Martin Simán
Director, Design and Interpretation
Centre of Excellence
AstraZeneca

Stuart Pocock
Professor of Medical Statistics,
London School of Hygiene & Tropical Medicine

Arne Ring
Head of the Statistics and Modelling Group, Diabetes Trials Unit
University of Oxford

Hans-Jürgen Wörle
Vice President & Therapeutic Area Head
Metabolism, Clinical Development and Medical Affairs
Boehringer-Ingelheim

Phil Ambery
Medical Director, Cardiovascular and Metabolic R&D
GlaxoSmithKline

Sandra Souza
Team Lead
Merck & Co.

Jamie Dwyer
Co-Director, Nephrology Clinical Trials Center
Vanderbilt University Medical Center

Bruce L. Riser
Director, Pharmaceuticals and Solutions, Medical Products Division,
Baxter Healthcare

John Wilding
Head, Department of Obesity and Endocrinology
University of Liverpool

Frederick Tam
Reader in Renal Medicine
Imperial College London

KEY REASONS TO ATTEND:

• Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4 inhibitors
• Review clinical results from the DEMAND study
• Utilise biomarkers and imaging for the development of novel cardiovascular and renal therapies
• Evaluate new targets to reduce hypertension and endothelial inflammation
• Ensure compliance with new FDA and EU guidelines when conducting risk-benefit assessments

PLUS ONE INTERACTIVE PRE–CONFERENCE WORKSHOP
Tuesday 27th November 2012,
The Copthorne Tara Hotel, London

Cardio-renal risk in type 2 diabetes information from clinical trials: what we have, what do we need to know?
Workshop leader: Luigi Gnudi, Professor of Diabetes and Metabolic Medicine, Honorary Consultant in Diabetes and Endocrinology, Head, Unit for Metabolic Medicine, Cardiovascular Division, King's College London
1.30pm-5.30pm

Supported by

Book at www.smi-online.co.uk/goto/diabetes-conference32.asp
Or contact Ninica Hussain on tel +44 0207 827 6186 or email nhussain@smi-online.co.uk

CPD Certified

Downloaded by: 54.70.40.11 - 11/24/2017 3:17:45 PM
Pulmonary Vascular Disorders

Editors
Marc Humbert
Rogerio Souza
Gérald Simonneau

Contents
Foreword
Preface
Updated Clinical Classification of Pulmonary Hypertension: Montani, D.; Simonneau, G.
Pathology of Pulmonary Arterial Hypertension: Dorfmüller, P.
Exercise Testing in Pulmonary Arterial Hypertension: Provencher, S.; Mainguy, V.
Noninvasive Exploration of the Pulmonary Circulation and the Right Heart: Vonk Noordegraaf, A.; Peacock, A.; Naeije, R.
Genetics of Pulmonary Arterial Hypertension and the Concept of Heritable Pulmonary Arterial Hypertension: Girerd, B.; Montani, D.; Yeici, A.; Eyrès, M.; Coulet, F.; Soubrier, F.; Humbert, M.
Drug- and Toxin-Induced Pulmonary Arterial Hypertension: Price, L.; Bouillon, K.; Wort, S.J.; Humbert, M.
Idiopathic Pulmonary Arterial Hypertension and Its Prognosis in the Modern Management Era in Developed and Developing Countries: Jiang, X.; Humbert, M.; Jing, Z.-C.
Pulmonary Arterial Hypertension Complicating Connective Tissue Disorders: de Paepe, J.; Hassoun, P.M.
Pulmonary Arterial Hypertension and HIV and Other Viral Infections: Degano, B.; Valmary, S.; Sitbon, O.; Humbert, M.
Portopulmonary Hypertension and Hepatopulmonary Syndrome: Savale, L.; Hervé, P.; Sitbon, O.
Pulmonary Hypertension in Congenital Heart Diseases: Tissot, C.; Beghetti, M.
Pulmonary Hypertension in Sickle Cell Disease: Parent, F.; Savale, L.; Maître, B.; Simonneau, G.
Pulmonary Veno-Occulsive Disease: Montani, D.; Huertas, A.; Dorfmüller, P.; Humbert, M.
Pulmonary Hypertension in Left Heart Disease: Adir, Y.; Galie, N.
Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease: Weitzenblum, E.

Humbert, M.

Choaoua, A.; Canuet, M.; Ducloné, A.; Kessler, R.
Pulmonary Hypertension Complicating Interstitial and Granulomatous Lung Diseases: Nunes, H.; Uzunhan, Y.; Gille, T.; Dauriat, G.; Braunier, M.; Kambouchner, M.; Valeyre, D.

Jing, Z.-C.

Acute Pulmonary Venous Thromboembolic Disease: Sanchez, O.; Meyer, G.
Anticoagulation for Venous Thromboembolism in the Modern Management Era: Le Gal, G.; Leroyer, C.; Mottier, D.

Degano, B.; Valmary, S.; Sitbon, O.; Humbert, M.

Meyer, G.

Cottin, V.; Khouatra, C.; Dupuis-Girod, S.; Cordier, J.-F.

Hoeper, M.M.

Rubin, L.J.

Author and Subject Index
Gender medicine is an important new field in health and disease. It is derived from top-quality research and encompasses the biological and social determinants that underlie the susceptibility to disease and its consequences. In the future, consideration of the role of gender will undoubtedly become an integral feature of all research and clinical care. Defining the role of gender in medicine requires a broad perspective on biology and diverse skills in biomedical and social sciences. When these scientific disciplines come together, a revolution in medical care is in the making. Covering twelve different areas of medicine, the practical and useful ‘Handbook of Clinical Gender Medicine’ provides up-to-date information on the role of gender in the clinical presentation, diagnosis, and management of a wide range of common diseases. The contributing authors of this handbook are all experts who, in well-referenced chapters, cogently and concisely explain how incorporation of gender issues into research can affect the medical understanding and treatment of heart disease, osteoporosis, arthritis, pain, violence, and malaria among other conditions. This intriguing and unique medical textbook provides readers with a valuable new perspective to understand biology and incorporate gender issues into the different branches of medicine.